Will CHRYSALIS turn into a butterfly?

[摘要] On 9 December 2021, the European Commission grantedconditional marketing approval (CMA) of amivantamab forthe treatment of adult patients with advanced non-smallcell lung cancer (NSCLC) with activating epidermal growthfactor receptor (EGFR) exon 20 insertion (Exon20ins)mutations, after failure of platinum-based therapy. Theapproval is mainly based on the findings of the single-arm,dose-escalation and dose-expansion phase I CHRYSALISstudy.1 The ongoing CHRYSALIS study is evaluating theefficacydas determined by overall response rate (ORR)dand safety of amivantamab in advanced NSCLC patientswith activating EGFR or mesenchymaleepithelial transitionfactor (c-MET) mutations or amplifications in six cohorts.The EGFR Exon20ins cohort consisted of 114 patients in thesafety and efficacy population.

[学科分类] 社会科学、人文和艺术（综合）